Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) – Pipeline Review, H2 2016’, provides in depth analysis on Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted pipeline therapeutics.

The report provides comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics and enlists all their major and minor projects

The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aptose Biosciences Inc.

Conatus Pharmaceuticals Inc.

LG Life Science LTD.

New World Laboratories, Inc.

Novelix Pharmaceuticals, Inc.

Pharmedartis GmbH

Shire Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) Overview 8

Therapeutics Development 9

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Products under Development by Stage of Development 9

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Products under Development by Therapy Area 10

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Products under Development by Indication 11

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Products under Development by Companies 15

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Products under Development by Universities/Institutes 18

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Companies Involved in Therapeutics Development 27

Aptose Biosciences Inc. 27

Conatus Pharmaceuticals Inc. 28

LG Life Science LTD. 29

New World Laboratories, Inc. 30

Novelix Pharmaceuticals, Inc. 31

Pharmedartis GmbH 32

Shire Plc 33

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Drug Profiles 34

BaxB-01 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

BaxG-03 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

BaxM-159 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

emricasan - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

flavokawain A - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Granzyme B/VEGF - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

HaA-4 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

nivocasan - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

NVX-207 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

NWL-53 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

plinabulin - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Recombinant Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecule to Activate Caspase-3 for Oncology - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Activate Caspase 3 for Oncology - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Dormant Projects 57

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Discontinued Products 62

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC

3.4.22.56) - Featured News & Press Releases 63

Jun 28, 2016: BeyondSprings Global Phase III Non-Small Cell Lung Cancer Clinical Trial for Plinabulin Launches in China 63

May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication 63

May 12, 2016: BeyondSpring Chief Medical Officer Served as Panelist at NewYorkBIO 64

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial 65

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data 67

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting 68

Feb 24, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin at 4th Annual Cancer Biopartnering & Investment Forum in NYC 68

Feb 08, 2016: BeyondSpring Pharmaceuticals’ Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC 68

Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis 69

Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis 70

Jan 07, 2016: BeyondSpring Pharmaceuticals to Present at 8th Annual Biotech Showcase 71

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 71

Jan 05, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin-Immune System Interactions at AACR’s 2016 Tumor Microenvironment Special Conference 73

Dec 21, 2015: BeyondSpring Pharmaceuticals Granted CTA by CFDA to initiate China Arm of Global Phase III Trial of Lead Asset Plinabulin 74

Nov 17, 2015: BeyondSpring Data Demonstrating Activity of Plinabulin in Kras-Mutant Tumors Presented at AACR-NCI-EORTC International Conference 2015 75

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Pipeline by Aptose Biosciences Inc., H2 2016 27

Pipeline by Conatus Pharmaceuticals Inc., H2 2016 28

Pipeline by LG Life Science LTD., H2 2016 29

Pipeline by New World Laboratories, Inc., H2 2016 30

Pipeline by Novelix Pharmaceuticals, Inc., H2 2016 31

Pipeline by Pharmedartis GmbH, H2 2016 32

Pipeline by Shire Plc, H2 2016 33

Dormant Projects, H2 2016 57

Dormant Projects (Contd..1), H2 2016 58

Dormant Projects (Contd..2), H2 2016 59

Dormant Projects (Contd..3), H2 2016 60

Dormant Projects (Contd..4), H2 2016 61

Discontinued Products, H2 2016 62

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports